<mark>SUI</mark>	PPLEI	MEN	TAL	TABLE:	Summary	of An	ntiretrov	riral Us	е
101			~ /		1 0 / 1 4 /		. —		

(% at Raseline % at Vear	5 and % Who Llead	Transitioned or Did Not Use in the Interval)	
(/0 at Dascille, /0 at 1 cal			

NRTI C PI C NNRTI C	Current Past Never Current Past Never Current Past Never Current Past	76.6 11.6 11.8 84.1 11.1 4.8 56.4 24.1 19.5	81.3 13.0 5.7 85.7 11.7 2.5 54.7 32.5	Initiated Use Continued Use Discontinued Use Not used* Initiated Use Continued Use Discontinued Use Not used Initiated Use	13.9 67.5 10.3 8.2 10.3 75.5 9.0 5.2
NRTI C PI C NNRTI C Lamivudine C	Never Current Past Never Current Past Never Current Past	11.8 84.1 11.1 4.8 56.4 24.1	5.7 85.7 11.7 2.5 54.7 32.5	Discontinued Use Not used* Initiated Use Continued Use Discontinued Use Not used	10.3 8.2 10.3 75.5 9.0 5.2
NRTI C PI C NNRTI C Lamivudine C	Current Past Never Current Past Never Current Past	84.1 11.1 4.8 56.4 24.1	85.7 11.7 2.5 54.7 32.5	Not used* Initiated Use Continued Use Discontinued Use Not used	8.2 10.3 75.5 9.0 5.2
PI C NNRTI C Lamivudine C	Past Never Current Past Never Current Past	11.1 4.8 56.4 24.1	11.7 2.5 54.7 32.5	Initiated Use Continued Use Discontinued Use Not used	10.3 75.5 9.0 5.2
PI C NNRTI C Lamivudine C	Past Never Current Past Never Current Past	11.1 4.8 56.4 24.1	11.7 2.5 54.7 32.5	Continued Use Discontinued Use Not used	75.5 9.0 5.2
PI C NNRTI C Lamivudine C	Never Current Past Never Current Past	4.8 56.4 24.1	2.5 54.7 32.5	Discontinued Use Not used	9.0 5.2
PI C NNRTI C Lamivudine C	Current Past Never Current Past	56.4 24.1	54.7 32.5	Not used	5.2
NNRTI C Lamivudine C	Past Never Current Past	24.1	32.5		
NNRTI C Lamivudine C	Past Never Current Past	24.1	32.5	Initiated Use	10.0
NNRTI C	Never Current Past				13.6
NNRTI C	Current Past	19.5		Continued Use	41.1
Lamivudine C	Past		12.8	Discontinued Use	17.6
Lamivudine C	Past			Not used	27.7
Lamivudine C		37.7	40.3	Initiated Use	18.7
Lamivudine C	Nover	19.1	35.6	Continued Use	21.6
	Never	43.2	24.1	Discontinued Use	20.3
				Not used	39.4
	Current	62.5	45.9	Initiated Use	10.3
	Past	26.4	47.6	Continued Use	35.6
Zidovudino	Never	11.1	6.5	Discontinued Use	29.1
Zidovudino C				Not used	25.0
	Current	32.5	24.5	Initiated Use	9.5
	Past	49.1	62.3	Continued Use	15.2
	Never	18.5	13.2	Discontinued Use	20.4
				Not used	55.0
Stavudine C	Current	38.0	9.4	Initiated Use	1.1
	Past	32.5	64.6	Continued Use	8.4
	Never	29.6	26.0	Discontinued Use	32.7
				Not used	57.9
Tenofovir C	Current	1.1	49.7	Initiated Use	48.6
	Past	0.2	7.6	Continued Use	1.1
	Never	98.7	42.8	Discontinued Use	7.3
				Not used	43.0
Didanosine C	Current	15.1	12.0	Initiated Use	6.7
	Past	30.6	43.0	Continued Use	5.2
	Never	54.3	45.1	Discontinued Use	15.3
				Not used	72.8
Abacavir C	Current	19.5	21.4	Initiated Use	10.9
	Past	11.5	26.8	Continued Use	10.5
	Never	69.0	51.8	Discontinued Use	17.2
				Not used	61.4
Emtricitabine C	Current	0.0	24.1	Initiated Use	24.1
	D 4	0.0	3.4	Continued Use	0 0
	Past Never	100.0	72.5	Discontinued Use	0.0 3.4

* means not used between FRAM1 and FRAM2

SUPPLEMENTAL 1	ABLE , continued:	Summary of Antiretroviral Use
----------------	--------------------------	-------------------------------

(% at Baseline, % at Year 5 and % Who Used, Transitioned or Did Not Use in the Interval)

ARV name		Baseline (%)	Year 5 (%)	Use c	or Transition (%
Zalcitabine	Current	0.4	0.2	Initiated Use	0.2
	Past	15.5	15.9	Continued Use	0.0
	Never	84.1	83.9	Discontinued Use	0.8
				Not used	99.0
Ritonavir	Current	27.9	42.6	Initiated Use	21.6
	Past	14.1	19.5	Continued Use	21.0
	Never	58.1	38.0	Discontinued Use	12.2
				Not used	45.3
Indinavir	Current	17.4	5.2	Initiated Use	1.5
	Past	31.2	46.1	Continued Use	3.8
	Never	51.4	48.6	Discontinued Use	16.1
				Not used	78.6
Nelfinavir	Current	16.8	6.1	Initiated Use	0.6
	Past	27.7	40.7	Continued Use	5.5
	Never	55.6	53.3	Discontinued Use	13.0
				Not used	80.9
Lopinavir	Current	10.3	18.7	Initiated Use	13.0
	Past	1.3	16.8	Continued Use	5.7
	Never	88.5	64.6	Discontinued Use	15.7
				Not used	65.6
Saquinavir	Current	8.4	5.9	Initiated Use	3.2
	Past	21.4	28.1	Continued Use	2.7
	Never	70.2	66.0	Discontinued Use	7.6
				Not used	86.6
Atazanavir	Current	0.0	18.9	Initiated Use	18.9
	Past	0.0	5.7	Continued Use	0.0
	Never	100.0	75.5	Discontinued Use	5.7
A	0	7.4		Not used	75.5
Amprenavir	Current	7.1	0.8	Initiated Use	0.0
	Past	2.3	11.7	Continued Use	0.8
	Never	90.6	87.4	Discontinued Use Not used	9.4 89.7
Ecompropovir	Current	0.0	6.1	Initiated Use	6.1
Fosamprenavir	Current Past	0.0	2.3	Continued Use	0.1
	Never	100.0	91.6	Discontinued Use Not used	2.3 91.6
Tipranavir	Current	0.0	0.4	Initiated Use	0.4
	Past	0.0	0.4	Continued Use	0.4
	Never	100.0	99.4	Discontinued Use	0.0
	INCAGI	100.0	33.4	Not used	0.2 99.4
Efavirenz	Current	24.7	28.3	Initiated Use	<u> </u>
	Past	13.2	28.3	Continued Use	14.5
	Never		20.3 43.4	Discontinued Use	
	INEVER	62.1	43.4		16.6

* means not used between FRAM1 and FRAM2

ARV name		Baseline (%)	Year 5 (%)	Use or Transition (%)	
Nevirapine	Current	12.2	11.5	Initiated Use	5.7
•	Past	13.2	21.2	Continued Use	5.9
	Never	74.6	67.3	Discontinued Use	9.2
				Not used	79.3
Delavirdine	Current	1.1	0.4	Initiated Use	0.0
	Past	3.8	5.2	Continued Use	0.4
	Never	95.2	94.3	Discontinued Use	1.5
				Not used	98.1
Entry Inhibitors	Current	0.4	2.5	Initiated Use	2.3
-	Past	0.2	1.7	Continued Use	0.2
	Never	99.4	95.8	Discontinued Use	1.5
				Not used	96.0

SUPPLEMENTAL TABLE, continued: Summary of Antiretroviral Use

* means not used between FRAM1 and FRAM2